We have reiterated our Neutral recommendation on XL Group plc ( XL ) as we expect the sustained low interest rate environment and catastrophe loss to weigh on the performance of the
The Medicines Company ( MDCO ) recently received good news with the company announcing positive results on its phase III antibiotic candidate, oritavancin.